Walvax May Be China’s Largest Biotech Conglomerate with Genor Biopharma Buy
HONG KONG – With its latest acquisition, China’s Walvax Biotechnology Co. is raising the ante on its investments to $600 million, hoping to leverage its growing size into a profitable pipeline of, among other things, monoclonal antibodies (MAbs).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter